

1645

CASE 4-31664A/USN

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Hesna J. Pfeiffer

Type or print name

Signature

Date

4/16/02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1645

BAIR ET AL.

APPLICATION NO: 10/024,935

FILED: DECEMBER 19, 2001

FOR: INHIBITORS OF THE E2F-1/CYCLIN INTERACTION FOR CANCER
THERAPYAssistant Commissioner for Patents
Washington, D.C. 20231INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.


RECEIVED

APR 24 2002

TECH CENTER 1600/2900

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

A handwritten signature in cursive script, appearing to read "Hesna J. Pfeiffer", written over a horizontal line.

Hesna J. Pfeiffer
Attorney for Applicants
Reg No. 22,640
(908) 522-6940

Novartis Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027

Date: 4/16/02

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-31664A/USN
APPLICATION NO.
10/024,935
APPLICANT
BAIR ET AL.
FILING DATE
DECEMBER 19, 2001

Group
1645

TECH CENTER 1600 2811

APR 24 2001

RECEIVED

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	5,719,296	2/17/98	Acton, III et al.	548	550	10/28/96
	AB	5,720,720	2/24/98	Laske et al.	604	49	3/15/96
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM						<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Chen et al., "Selective Killing of Transformed Cells by Cyclin/Cyclin-Dependent Kinase 2 Antagonists", Proc. Natl. Acad. Sci. USA, Vol. 96, pp. 4325-4329 (1999).
	AS	Sharma et al., "Identification of E2F-1/Cyclin A Antagonists", Bioorg. Med. Chem. Lett., Vol. 11, pp. 2449-2452 (2001).
	AT	Laske et al., "Tumor Regression with Regional Distribution of the Targeted Toxin TF-CRM107 in Patients with Malignant Brain Tumors", Nature Medicine, Vol. 3, No. 12, pp. 1362-1368 (1997).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609. Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-31664A/USN
APPLICATION NO.
10/024,935
APPLICANT
BAIR ET AL.
FILING DATE
DECEMBER 19, 2001

Group
1645

TECH CENTER 1600 2900

APR 24 2002

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AA	Fueyo et al., "Overexpression of E2F-1 in Glioma Triggers Apoptosis and Suppresses Tumor Growth <i>In Vitro</i> and <i>In Vivo</i> ", <i>Nature Medicine</i> , Vol. 4, No. 6, pp. 685-690 (1998).
AB	Vivès et al., "A Truncated HIV-1 Tat Protein Basic Domain Rapidly Translocates through the Plasma Membrane and Accumulates in the Cell Nucleus", <i>J. Biol. Chem.</i> , Vol. 272, No. 25, pp. 16010-16017 (1997).
AC	Bonfanti et al., "p21 ^{WAF1} -derived Peptides Linked to an Internalization Peptide Inhibit Human Cancer Cell Growth", <i>Cancer Res.</i> , Vol. 57, pp. 1442-1446 (1997).
AD	Ball et al., "Cell-Cycle Arrest and Inhibition of Cdk4 Activity by Small Peptides Based on the Carboxy-Terminal Domain of p21 ^{WAF1} ", <i>Current Biology</i> , Vol. 7, No. 1, pp. 71-79 (1996).
AE	Adams et al., "Identification of a Cyclin-cdk2 Recognition Motif Present in Substrates and p21-Like Cyclin-Dependent Kinase Inhibitors", <i>Mol. Cell. Biol.</i> , Vol. 16, No. 12, pp. 6623-6633 (1996).
AF	Chen et al., "Cyclin-Binding Motifs Are Essential for the Function of p21 ^{CIP1} ", <i>Mol. Cell. Biol.</i> , Vol. 16, No. 9, pp. 4673-4682 (1996).
AG	Krek et al., "Cyclin A-Kinase Regulation of E2F-1 DNA Binding Function Underlies Suppression of an S Phase Checkpoint", <i>Cell</i> , Vol. 83, pp. 1149-1158 (1995).
AH	Kowalik et al., "E2F1 Overexpression in Quiescent Fibroblasts Leads to Induction of Cellular DNA Synthesis and Apoptosis", <i>J. Virol.</i> , Vol. 69, No. 4, pp. 2491-2500 (1995).
AI	Wu et al., "p53 and E2F-1 Cooperate to Mediate Apoptosis", <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 91, pp. 3602-3606 (1994).
AJ	
AK	
AL	
AM	
AN	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.